The Clinical Benefits of the DiviTum® TKa Test

The DiviTum® TKa test can help oncologists make confident treatment decisions

  • Allows health care providers to easily track a patient’s response early on—and at any time point as clinically indicated—throughout treatment.
  • Complements traditional imaging—particularly if CT scans are difficult to interpret.

Validated to be prognostic for disease progression and overall survival1-2,*

  • Lower DiviTum TKa levels are associated with lower likelihood of disease progression*

Helps health care providers determine...

  • Which patients are—or are not—responding optimally to CDK4/6 inhibitor therapy and may benefit from continuing therapy3,4
Download Info Sheet

*In the randomized, phase III, SWOG S0226 clinical trial, DiviTum TKa demonstrated a negative predictive value (NPV) of 97% and 94% within 30 and 60 days post testing, respectively. This clinical validation study assessed data from 1546 banked blood samples from 454 women with HR+ mBC who were treated with first-line endocrine therapy (anastrozole alone or anastrozole plus fulvestrant).

Treatment Response Patterns

References:

1. Bergqvist M, et al. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Biomarkers January 2023

2. Paoletti C, et al. Evaluating serum thymidine kinase 1 in patients with hormone receptor-positive metastatic breast cancer receiving first-line endocrine therapy in the SWOG S0226 trial. Clin Cancer Res. 2021;27(22):6115-6123.

3. Malorni L, et al. International Breast Cancer Study Group; Breast International Group and PYTHIA Collaborators. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer. 2022;164:39-51.

4. Malorni L, et al. Serum thymidine kinase activity in patients with HRpositive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. Eur J Cancer. 2023; 186: 1–11. Eur J Cancer 2023; 186: 1–11.

PLEASE SELECT ONE

Please specify your home location

USA
Europe/Rest of World